Clair Health

Summary

Clair Health is building a noninvasive wearable focused on continuous hormone intelligence for women. Its public materials describe a wrist-worn device and app designed to infer hormonal state from multimodal physiological signals rather than from blood draws, urine tests, or calendar-based cycle prediction.

Clair is best understood as an early women’s health sensing and AI company, not as a traditional period tracker or a general fitness wearable. Its central thesis is that hormone state can be inferred from patterns across cardiovascular, thermoregulatory, autonomic, electrodermal, respiratory, sleep, activity, and body-composition signals when those signals are captured continuously and modeled against hormone ground truth.

Why It Matters

Clair Health matters because women’s health has historically lacked continuous, accessible, personalized biological data. Most consumer cycle tools rely on calendar prediction, self-reported symptoms, temperature snapshots, or episodic hormone testing. Clair is trying to move the category toward continuous biological sensing, where the cycle is treated as a primary signal rather than background noise.

As a Health AI category signal, Clair shows how wearable hardware, sensor fusion, and domain-specific models may converge into a new class of hormone-aware health systems. Its work also raises important evidentiary questions: how to validate inferred biological states, how to handle confounders, and how to separate wellness insights from medical claims.

Best Read As

Clair Health is best read as a women’s health AI and continuous hormone-intelligence company, not as a generic wearable, simple period tracker, or fertility-only app.

Its public positioning is closer to sensor-based physiological inference and personalized hormone context than to direct diagnostic testing, autonomous medical advice, or conventional consumer fitness tracking.

Domains

• Women’s health
• Hormone intelligence
• Continuous wearable sensing
• Cycle-phase and ovulation-related insight
• Sleep, recovery, readiness, and activity context
• Noninvasive physiological signal interpretation
• General wellness and future regulated reproductive health monitoring

Modalities

• Wrist-worn wearable sensing
• Multimodal physiological signal capture
• Heart rate, HRV, temperature, motion, sleep, respiration, electrodermal activity, and bioimpedance signals
• Sensor-fusion models trained against hormone ground truth
• Cycle-phase classification and hormonal trend tracking
• Mobile-app insight delivery
• On-device sensitive data processing posture

Signal Indicators

• Clair publicly describes itself as building the first wearable continuous hormone monitor.
• The company says its system tracks estrogen, progesterone, LH, FSH, and PdG-related hormone signals.
• Its official science overview describes 130+ mechanistic biomarkers across multiple sensor modalities.
• Clair reports prototype validation on 40+ women across 127 complete menstrual cycles and more than 5,000 days of continuous physiological data.
• The company states that Clair 1.0 will launch as a general wellness device, while Clair 2.0 will pursue FDA 510(k) clearance for medical-grade claims.
• Clair states that sensitive health data is processed on-device and does not leave the user’s phone.
• MobiHealthNews reported that Clair raised $11.6 million in funding led by Khosla Ventures.
• Public coverage identifies Clair as founded by Stanford graduates Jenny Duan and Abhinav Agarwal.

Architecture and Stance

Clair’s architecture is publicly framed around multimodal sensing and physiological inference. Rather than directly measuring hormones through blood or urine samples, Clair observes downstream physiological changes and uses sensor-fusion models to infer hormonal state from patterns across multiple biological systems.

The company’s stance is hormone-first rather than fitness-first. Clair argues that many wearables treat cyclical female physiology as noise, while its system is designed around the hormonal cycle as the primary signal. That position gives the company a distinct technical and category posture within women’s health AI.

Governance Posture

Clair’s strongest visible governance signals are its explicit regulatory staging, its on-device-first privacy posture, and its willingness to distinguish between current wellness capabilities and future medical-grade claims. The company states that Clair 1.0 is a general wellness device and that quantitative hormone reporting will wait for the regulatory threshold associated with Clair 2.0.

The company also publicly acknowledges unresolved scientific questions, including confounders, irregular-cycle performance, and the need for larger independent validation. That transparency improves the profile, but it also means Clair should be described as an early, evidence-building company rather than as a fully validated clinical monitoring platform.

Scale and Trajectory

Clair is early-stage but visible. Its public trajectory includes a waitlist and founding membership model, seed funding led by Khosla Ventures, public science materials, and a stated clinical study roadmap. The company appears to be moving from prototype validation and market reservation into production hardware and broader clinical validation.

The strongest current signal is category ambition and technical specificity, not mature clinical deployment. Clair may become an important company to watch if it can validate noninvasive hormone inference at larger scale, preserve a strong privacy posture, and navigate the boundary between wellness insight and regulated medical claims.

Recent Public Updates

• Clair Health Raises $11.6M for Women’s Hormone-Monitoring Wearable reported an $11.6 million funding round led by Khosla Ventures, with participation from a16z speedrun, AI in Health Fund, Brydge Club, Cartan Capital, and Anne Wojcicki.
• How It Works: Your Questions, Answered published Clair’s detailed public explanation of its continuous hormone-monitoring approach, validation claims, confounder limitations, regulatory staging, and clinical study roadmap.

What Is Still Unclear

Public information does not yet fully show how Clair’s production hardware will perform at scale, how independent validation results will compare with early prototype metrics, or how the system will perform across larger populations, irregular cycles, perimenopause, hormonal contraception, hormone replacement therapy, and real-world confounders.

The strongest current signal is a technically specific, evidence-building approach to noninvasive hormone intelligence. It should not yet be read as proof of mature clinical-grade hormone monitoring, FDA-cleared quantitative hormone measurement, or broad real-world medical deployment.